Patient demographics (intent-to-treat population)
| Placebo (N=20) | FF/VI 400/25 μg (N=40) | Total (N=60) | |
| Age (years), mean (SD) | 63.8 (6.01) | 63.5 (7.10) | 63.6 (6.71) |
| Male, n (%) | 15 (75) | 25 (63) | 40 (67) |
| Race: white, n (%) | 20 (100) | 40 (100) | 60 (100) |
| Height (cm), mean (SD) | 174.6 (6.64) | 174.1 (8.11) | 174.3 (7.60) |
| Weight (kg), mean (SD) | 82.44 (16.276) | 78.66 (14.169) | 79.92 (14.875) |
| Pre-bronchodilator FEV1 (l), mean (SD) | 1.710 (0.4118) | 1.628 (0.4817) | 1.655 (0.4577) |
| Post-bronchodilator FEV1 (l), mean (SD) | 1.939 (0.4454) | 1.860 (0.4747) | 1.886 (0.4629) |
| Post-bronchodilator per cent predicted FEV1* (%), mean (SD) | 60.1 (10.86) | 58.5 (10.03) | 59.1 (10.25) |
| Per cent reversibility in FEV1 (%), mean (SD) | 14.5 (12.48) | 16.2 (14.14) | 15.6 (13.53) |
| Post-bronchodilator FEV1/FVC, mean (SD) | 55.3 (8.41) | 52.7 (8.68) | 53.6 (8.61) |
↵* FEV1 calculated using Third National Health and Nutrition Examination Survey (NHANES III) values.
FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FVC, forced vital capacity; VI, vilanterol.